jeudi 8 février 2018

Onco Actu du 8 février 2018


2.6 Etiologie - Environnement

WHO rebuts House committee criticisms about glyphosate cancer warning [Science]

How Toxic is the World’s Most Popular Herbicide Roundup? [The Scientist]

3.1.1 Prévention - Tabac - e-cigs

Misconceptions about e-cigarette safety might be stopping smokers using them to quit [Cancer Research UK]

U.S. senators ask FDA to reject Philip Morris' iQOS application [Reuters]

3.8 Prévention - Alimentation

Manipulating a mouse’s diet can stop breast cancer spreading [Cancer Research UK]

Spread of breast cancer linked to compound in asparagus and other foods [The Guardian]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Pancreatic cancer patients should be offered early scans to avoid unnecessary surgery, says NICE [NICE]

4.7 Dép., diag. & prono. - Col de l'utérus

More evidence ‘Unfortunate Experiment’ led to cancer – In the News [Science Media Center]

5.12.2 Immunothérapies - CAR-T

Scotland’s TCB inks CAR-T deal with Japan’s NIPRO [PharmaTimes]

Breakthrough cancer therapy raises tough questions about drug costs, value [The Enquirer]

5.2 Pharma

At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA [Xconomy]

Verastem submits new drug application to U.S. FDA for duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma [Verastem]

Verastem takes AbbVie’s blood cancer castoff to the FDA [EndPoints]

Sanofi sounds taps on a half dozen drug programs in latest pipeline cleanup [EndPoints]

5.2.3 Pharma - économie

With startup, George Church bets cryptocurrency will boost genome sequencing [STAT]

This new company wants to sequence your genome and let you share it on a blockchain [MIT Technology Review]

5.4 Traitements - Economie

Patients to benefit from myeloma treatment through CDF deal [NICE]

NICE Publishes Technology Appraisal Guidance About Intrabeam Radiotherapy System for Adjuvant Treatment of Early Breast Cancer [ESMO]

5.5.14 ASCO (vessie)

Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Genitourinary (GU) Tumors [Exlixis]

5.5.3 ASCO (prostate)

Myriad's myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation [Myriad]

Bayer to showcase latest prostate cancer research at ASCO GU 2018 Cancer Symposium [Bayer]

6. Lutte contre les cancers

SCO Examines the Current Oncology Clinical Pathways Landscape [ASCO]

The Future of Precision Medicine in Australia [ACOLA]

Last Month in Oncology with Dr. Bishal Gyawali: January 2018 [ecancernews]

6.1 Observation

Reasons Not To Freak Out About Risk Of Heart Disease After Breast Cancer [Forbes]

Many breast cancer survivors may die of heart disease, doctors warn [Reuters]

6.10 Politiques

Germany's Angela Merkel finally reaches coalition deal with SPD [DW]

6.6 Publications

Let’s move beyond the rhetoric: it’s time to change how we judge research [Nature]